Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company developing drugs for CNS disorders. Its lead product is TLANDO, an oral testosterone replacement therapy. Pipeline candidates include TLANDO XR, LPCN 1148, LPCN 1154, LPCN 2101, and LPCN 2203. The company also developed LPCN 1144, which completed Phase 2 testing, and LPCN 1107, currently in Phase 3 studies for recurrent preterm birth prevention. Founded in 1997, the company is headquartered in Utah.
Overview
Strengths
- Conservative leverage: net debt is only 0.5x EBITDA.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 7.6% in each of the last 6 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -2,424% to 19% over the last 4 years, with operating losses in 3 of them.
- Shareholder dilution: the share count has grown by 5.8% a year over the last three years.
Key Financial Data